NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Avenzo Goes Public: $215 Million Merger with Rallybio to Fight Cancer

Rallybio merges with Avenzo to boost cancer drug development; new AVZO company gets $215M funding and Nasdaq listing.

Avenzo Goes Public: $215 Million Merger with Rallybio to Fight Cancer
Credit: Avenzo Therapeutics
Already have an account? Sign in.
Featured/ 06/01/2026 · 9:29 AM
RLYB
/ Don’t stop at just one post.

Related↓

Rallybio Merges with Candid Therapeutics in $500M+ Deal to Build Autoimmune Powerhouse
03/02/2026 · 9:28 AM

Rallybio Merges with Candid Therapeutics in $500M+ Deal to Build Autoimmune Powerhouse

Rallybio announces a reverse merger with Candid Therapeutics, forming a new Nasdaq-listed company focused on T-cell therapies for autoimmune diseases, backed by over $500M in funding through 2030.

/ Subscriber only
/ Read more

Feed↓

Evolus shares fall after FDA calls Jeuveau Instagram post misleading
10/02/2026 · 4:04 PM

Evolus shares fall after FDA calls Jeuveau Instagram post misleading

The FDA says an Evolus Instagram post overstated Jeuveau benefits and downplayed risks. The firm has 15 working days to respond.

/ Subscriber only
Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion
Featured/ 10/02/2026 · 3:45 PM

Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion

Novartis will pay $575 million upfront for worldwide rights to Abogen's mRNA T-cell engager, plus up to $7.2 billion in milestones.

/ Subscriber only
20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18
10/02/2026 · 2:42 PM

20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18

Planet Labs put 20 satellites in orbit on Oct. 1, 2026, including a Google TPU prototype, Tanager-2 methane sensor, and 18 SuperDoves.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe